Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05737706 at ClinicalTrials.govnct06040541 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct05382559 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct01676259 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
https://doi.org/10.1200/jco.2023.41.4_suppl.tps764
nct06056024 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct06625320 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct04330664 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct05920356 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
nct03948763 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, <i>KRAS</i> G12C-mutated NSCLC (CodeBreaK 202).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps8653
nct06127940 at ClinicalTrials.govDocuments that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
Documents that mention this clinical trial
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
https://doi.org/10.1136/bmjonc-2025-000946
- License Information
